Communications Biology (Aug 2024)

Intestinal microbiota homeostasis analysis in riboflavin-treated alcoholic liver disease

  • Xiuyun Shen,
  • Chunpeng Shi,
  • Jincheng Xu,
  • Fengnan Zhi,
  • Kunpeng Luo,
  • Yuzhu Di,
  • Wanhong Li,
  • Wanjing Ma,
  • Yanan Jiang,
  • Hui Sun

DOI
https://doi.org/10.1038/s42003-024-06722-4
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 12

Abstract

Read online

Abstract Alcoholic liver disease (ALD) is a disease with high incidence, limited therapies, and poor prognosis. The present study aims to investigate the effect of riboflavin on ALD and explore its potential therapeutic mechanisms. C57BL/6 mice were divided into the control, alcohol, and alcohol+ riboflavin groups. 16S rRNA-seq and RNA-seq analysis were utilized to analyze the polymorphism of intestinal microbiota and the transcriptome heterogeneity respectively. KEGG and GO enrichment analysis were performed. CIBERSORTx was applied to evaluate the immune cell infiltration level. Publicly available transcriptome data of ALD was enrolled and combined with the RNA-seq data to identify the immune subtypes of ALD. Pathological and histology analysis demonstrated that riboflavin reversed the progression of ALD. 16S rRNA-seq results showed that riboflavin could regulate alcohol-induced intestinal microbiota alteration. Intestinal microbiota polymorphism analysis indicated that VLIDP may contribute to the progression of ALD. Based on the VLIDP pathway, two subtypes were identified. Immune microenvironment analysis indicated that the upregulated inflammatory factors may be important regulators of ALD. In conclusion, intestinal microbiota homeostasis was associated with the protective effect of riboflavin against ALD, which was likely mediated by modulating inflammatory cell infiltration. Riboflavin emerges as a promising therapeutic candidate for the management of ALD.